Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 3, 2025

Keywords

ClinConnect Summary

The BOMASH study is a research trial that aims to understand more about certain liver diseases, specifically Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH). The researchers want to find out which factors can help predict how these conditions will progress, especially for patients who might need a liver transplant or could develop liver cancer (HCC). This study will include patients who have been diagnosed with these liver diseases, whether they are new diagnoses or part of ongoing care at the medical center.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of MASLD or MASH based on recent guidelines. Participants may also be asked to provide a biological sample, such as a liver biopsy, if their doctor thinks it's necessary for diagnosis. The study is currently recruiting participants, and there are no specific exclusions, so anyone fitting the criteria is welcome to join. By participating, individuals can contribute to important research that may help improve the understanding and treatment of liver diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with a diagnosis of MASLD, established according to the most recent published guidelines (EASL, EASD, EASO)
• • Age ≥18 years
• Inclusion Criteria for Biological Sample Collection:
• • Patients requiring liver biopsy for diagnostic purposes, as indicated by the most recent published guidelines (EASL, EASD, EASO)
• Exclusion Criteria:
• • No exclusion criteria.